7Baggers

Applied DNA Sciences, Inc
(NASDAQ:APDN) 

APDN stock logo

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes ...

Founded: 1983
Sector: Industrials
Industry: Security & Protection Services
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2010-09-30 2010-06-30 2010-03-31 2009-12-31 
                                                            
      revenues
    		                               637,583 652,896 1,324,114 3,980,265 2,267,671 1,518,761 1,241,802 518,924.5 841,197 637,146 597,354 729,105 644,842 344,605 317,670           
      product revenues
    		1,007,903 555,093 184,400 195,262 548,638 495,847 127,727 246,644 393,125 307,317 87,385 316,950 297,454 516,396 428,377 219,765 826,311 1,141,005 639,637 965,110 392,599 171,261 321,875 597,394 393,758 486,341 350,133 846,941 1,493,449 689,188 704,417                          
      service revenues
    		16,208 10,301 15,029 109,131 214,184 374,444 359,900 226,145 205,486 247,147 170,053 425,694 169,058 232,061 188,379 182,796 139,273 -2,895,424 1,060,683 1,706,432 1,660,858 607,207 562,447 597,971 622,597 557,605 297,544 298,556 303,933 216,185 198,591                          
      total revenues
    		1,024,111 565,394 199,429 304,393 983,374 1,196,617 813,107 797,519 929,631 891,164 779,736 2,917,341 4,407,614 5,262,752 3,559,317 4,296,371 4,165,706 3,039,735 1,700,320 2,671,542 2,053,457 778,468 884,322 1,195,365 1,016,355 1,043,946 647,677 1,145,497 1,797,382 905,373 903,008                          
      yoy
    		4.14% -52.75% -75.47% -61.83% 5.78% 34.28% 4.28% -72.66% -78.91% -83.07% -78.09% -32.10% 5.81% 73.13% 109.33% 60.82% 102.86% 290.48% 92.27% 123.49% 102.04% -25.43% 36.54% 4.35% -43.45% 15.31% -28.28%                              
      qoq
    		81.13% 183.51% -34.48% -69.05% -17.82% 47.17% 1.95% -14.21% 4.32% 14.29% -73.27% -33.81% -16.25% 47.86% -17.16% 3.14% 37.04% 78.77% -36.35% 30.10% 163.78% -11.97% -26.02% 17.61% -2.64% 61.18% -43.46% -36.27% 98.52% 0.26%                           
      cost of product revenues
    		197,325 250,037 367,409 299,263 367,304 264,052 285,616 230,188 340,301 282,545 204,777 368,902 369,563 365,378 904,758 307,049 434,929                                        
      gross profit
    		826,786 315,357 -167,980 5,130 370,847 684,107 244,899 245,232 295,651 231,097 78,996 1,269,318 1,807,435 2,377,683 416,759 1,039,258 1,109,138                                    74,858 150,537 173,239 58,281 
      yoy
    		122.95% -53.90% -168.59% -97.91% 25.43% 196.03% 210.01% -80.68% -83.64% -90.28% -81.05% 22.14% 62.96%                                            
      qoq
    		162.17% -287.73% -3374.46% -98.62% -45.79% 179.34% -0.14% -17.05% 27.93% 192.54% -93.78% -29.77% -23.98% 470.52% -59.90% -6.30%                                     -50.27% -13.10% 197.25%  
      gross margin %
    		80.73% 55.78% -84.23% 1.69% 37.71% 57.17% 30.12% 30.75% 31.80% 25.93% 10.13% 43.51% 41.01% 45.18% 11.71% 24.19% 26.63% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% Infinity% Infinity% Infinity% Infinity% 
      operating expenses:
    		                                                        
      selling, general and administrative
    		2,591,647 13,348,510 2,444,988 2,930,627 2,983,284 2,633,098 2,684,444 2,678,894 3,000,208 3,084,348 3,310,910 3,292,304 3,522,715 2,625,357 3,873,345 3,013,967 4,662,173 2,312,209 3,239,953 3,557,487 2,407,223 2,528,914 3,082,380 3,571,546 2,882,158 1,996,604 2,593,154 2,790,398 3,402,817 3,230,371 3,900,917 2,623,151 2,707,420 3,554,362 3,658,046 3,508,455 2,901,207 4,671,490 3,156,122 2,948,452 3,297,739 3,845,578 2,682,115 3,240,815 2,754,407 2,521,167 1,886,159 1,752,501 1,824,646 2,152,428 3,859,521 1,580,788 1,811,004 2,510,119 1,262,833 1,542,135 
      realized gain on derivative written call options
    		-21,573                                                        
      loss from change in fair value of digital assets
    		2,086,347                                                        
      loss from fair value measurement of investment in digital asset trust
    		2,548,799 3,484,009                                                       
      research and development
    		372,149 458,562 3,383,981 768,563 849,358 1,015,010 831,710 913,031 913,194 935,815 938,907 836,123 988,744 971,304 912,881 863,025 1,080,096 1,113,393 1,029,627 874,055 719,668 651,377 709,564 716,692 625,006 669,813 740,067 524,746 603,095 635,893 518,628 832,227 1,077,916 471,934 673,636 310,093 373,380 278,288 215,334 266,331 359,782 459,304 183,348 184,981 176,485 147,666 158,141 99,958 96,097 78,473 107,231 47,988 31,017 18,142 20,654 6,148 
      total operating expenses
    		7,577,369 19,023,638 5,828,969 3,699,190 3,832,642 3,648,108 3,516,154 3,591,925 3,913,402 4,020,163 4,249,817 4,128,427 4,511,459 3,596,661 4,786,226 3,876,992 5,742,269 4,547,217 4,517,351 4,630,923 3,214,206 3,277,964 3,926,996 4,410,107 3,630,163 2,811,697 3,490,869 3,715,663 4,167,353 4,029,632 4,581,522 3,603,906 3,953,977 4,244,642 4,468,179 3,939,887 3,397,666 5,059,504 3,488,270 3,328,207 3,764,331 4,410,097 3,081,432 3,488,076 2,952,722 2,689,828 2,057,821 1,955,797 2,019,451 2,329,274 4,057,700 1,720,668 1,935,316 2,621,084 1,375,837 1,641,729 
      income from operations
    		-6,750,583 -18,708,281 -5,996,949 -3,694,060 -3,461,795 -2,964,001 -3,271,255 -3,346,693 -3,617,751 -3,789,066 -4,170,821 -2,859,109 -2,704,024 -1,218,978 -4,369,467 -2,837,734 -4,633,131 -4,457,241 -3,367,488 -2,315,991 -1,431,632 -2,632,637 -3,196,159 -3,465,401 -2,866,370 -2,139,904 -3,174,632 -2,842,846 -2,602,319 -3,421,631 -3,953,346 -2,409,782 -3,422,341 -2,920,528 -487,914 -1,672,216 -1,878,905 -3,817,702 -2,842,744 -2,487,010 -3,127,185  -2,352,327 -2,843,234 -2,608,117 -2,372,158    -1,812,370   -1,860,458 -2,470,547   
      yoy
    		95.00% 531.18% 83.32% 10.38% -4.31% -21.77% -21.57% 17.05% 33.79% 210.84% -4.55% 0.75% -41.64% -72.65% 29.75% 22.53% 223.63% 69.31% 5.36% -33.17% -50.05% 23.03% 0.68% 21.90% 10.15% -37.46% -19.70% 17.97% -23.96% 17.16% 710.25% 44.11% 82.15% -23.50% -82.84% -32.76% -39.92%  20.85% -12.53% 19.90%     30.89%    -26.64%       
      qoq
    		-63.92% 211.96% 62.34% 6.71% 16.79% -9.39% -2.25% -7.49% -4.52% -9.15% 45.88% 5.74% 121.83% -72.10% 53.98% -38.75% 3.95% 32.36% 45.40% 61.77% -45.62% -17.63% -7.77% 20.90% 33.95% -32.59% 11.67% 9.24% -23.95% -13.45% 64.05% -29.59% 17.18% 498.57% -70.82% -11.00% -50.78% 34.30% 14.30% -20.47%   -17.27% 9.01% 9.95%        -24.69%    
      operating margin %
    		-659.17% -3308.89% -3007.06% -1213.58% -352.03% -247.70% -402.32% -419.64% -389.16% -425.18% -534.90% -98.00% -61.35% -23.16% -122.76% -66.05% -111.22% -146.63% -198.05% -86.69% -69.72% -338.18% -361.42% -289.90% -282.02% -204.98% -490.16% -248.18% -144.78% -377.93% -437.80% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% -Infinity% NaN% NaN% -Infinity% -Infinity% NaN% NaN% 
      interest income
    		3,761 9,143 24,153 40,267 60,340 71,440 91,329 36,295 15,352 33,323 41,224 26,783 3,639 3,686 1,387  273 1,700 3,572 13,841 -38,177 -37,417 -31,611      228 1,204 1,331 1,437 2,660 2,845 3,339 5,052 16 -31,875 -11,813 111 239 434               
      unrealized gain on change in fair value of warrants classified as a liability
    		 370 790 6,410 68,430 244,000 -134,000 5,160,000 1,765,000 2,639,000 519,700 -278,400 3,250,900                                            
      other income
    		81,663 92,586   -3,095  183 -101 4,581 -13,538 -5,754 -3,469 661 8,846         -6,550    -9,080     -6,731 52,670 -8,587 -11,460 -3,718 -6,693 -3,685 -6,272 52,299 -79,389 155,417               
      income before provision for income taxes
    		-6,665,159 -18,606,182 -6,054,808 -3,647,914 -3,336,120 -2,668,713 -3,313,743 1,849,501 -4,493,783 -1,130,281 -3,615,651 -3,114,195 551,176 -3,844,246 -664,554 -1,124,797 -4,720,911 -4,507,584 -3,446,715 -1,517,078 -1,477,911 -2,686,757 -3,234,320 -3,475,283 -2,887,723 -2,146,209 -3,183,712    -3,961,384                          
      income tax provision benefit
    		                                                        
      net income from continuing operations
    		-6,665,159 -18,606,182 -5,370,693 -3,647,914                                                     
      net loss from discontinued operations, net of tax
    		  10,389 -336,195                                                     
      net income
    		-6,665,159 -18,606,182 -5,360,304 -3,984,109 -3,336,120 -2,668,713 -3,313,743 1,849,501 -4,493,783 -1,130,281 -3,615,651 -3,114,195 551,176 -3,844,246 -664,554 -1,124,797 -4,720,911 -4,507,584 -3,446,715 -1,517,078 -1,477,911 -2,686,757 -3,234,320 -3,475,283 -2,887,723 -2,146,209 -3,183,712 -2,854,678 -2,610,849 -3,428,856 -3,961,384 -2,415,076 -3,367,011 -2,926,270 -496,035 -1,670,882 -1,885,582 -7,828,644 -2,105,518 -1,919,057 -2,750,436  -3,718,471 -2,135,612 -3,127,631 -8,704,757   -1,543,882  -4,417,364 -2,154,995 -2,115,755 -2,596,935 -1,389,202 -1,808,008 
      yoy
    		99.79% 597.20% 61.76% -315.42% -25.76% 136.11% -8.35% -159.39% -915.31% -70.60% 444.07% 176.87% -111.68% -14.72% -80.72% -25.86% 219.43% 67.77% 6.57% -56.35% -48.82% 25.19% 1.59% 21.74% 10.60% -37.41% -19.63% 18.20% -22.46% 17.17% 698.61% 44.54% 78.57% -62.62% -76.44% -12.93% -31.44%  -43.38% -10.14% -12.06%    102.58%    -27.03%  217.98% 19.19%     
      qoq
    		-64.18% 247.11% 34.54% 19.42% 25.01% -19.47% -279.17% -141.16% 297.58% -68.74% 16.10% -665.01% -114.34% 478.47% -40.92% -76.17% 4.73% 30.78% 127.19% 2.65% -44.99% -16.93% -6.93% 20.35% 34.55% -32.59% 11.53% 9.34% -23.86% -13.44% 64.03% -28.27% 15.06% 489.93% -70.31% -11.39% -75.91% 271.82% 9.72% -30.23%   74.12% -31.72% -64.07%      104.98% 1.85% -18.53% 86.94% -23.16%  
      net income margin %
    		-650.82% -3290.83% -2687.83% -1308.87% -339.25% -223.02% -407.54% 231.91% -483.39% -126.83% -463.70% -106.75% 12.51% -73.05% -18.67% -26.18% -113.33% -148.29% -202.71% -56.79% -71.97% -345.13% -365.74% -290.73% -284.13% -205.59% -491.56% -249.21% -145.26% -378.72% -438.69% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      less: net loss attributable to noncontrolling interest
    		-68 12,619 88,530 38,746 31,945 29,301 17,000 30,295 23,309 25,181 23,387 14,429 37,167 874 1,335 576  -3,509 -2,278 278                                     
      net loss attributable to bnb plus corp.
    		-6,665,227 -18,593,563                                                       
      deemed dividend related to warrant modifications
    		 -32,827  -15,500,244 -23,919,429 -14,907,223   -155,330 -77,757                                               
      net loss attributable to common stockholders
    		-6,665,227 -18,626,390   -27,223,604 -17,546,635    -1,182,857 -3,592,264 -3,099,766   -663,219 -1,124,221 -4,721,766 -4,511,093 -3,448,993                                      
      net income per share
    		-0.68 -2.08 121.67 -33.41 -15.35 -0.56 0.33 0.47 -5.31 -0.09 -0.27 -0.24 0.05 -0.3 0.01 -0.13 -0.63 -0.62 -0.46 -0.21 -0.04 -0.08 -0.11 -0.12 -0.1 -0.07 -0.12 -0.11 -0.1 -0.13 -0.16 -0.1 -0.14 -0.13  -0.08 -0.11 -0.51 -0.003    -0.01   -0.01     -0.01 -0.01 -0.01 -0.01  -0.01 
      weighted-average shares outstanding-basic and diluted
    		9,735,631 8,942,937 517,671    3,966,026    13,075,416    8,967,704   6,916,999      29,497,619   27,674,340 26,378,991 26,374,023   23,693,096                         
      loss from fair value measurement of digital assets
    		 1,732,557                                                       
      net income from discontinued operations, net of tax
    		                                                        
      transaction costs allocated to warrant liabilities
    		        -633,198                                                
      unrealized loss on change in fair value of warrants classified as a liability - warrant modification
    		                                                        
      loss on issuance of warrants
    		        -1,633,767                                                
      other expense
    		  -82,802 -531  -20,152         113,082 -45,263 -88,053 -52,043 -82,799 -54,873 -8,102 -16,703  -267 -21,353 -6,305    -8,429 -9,369                          
      provision for income taxes
    		                                                        
      net income attributable to applied dna sciences, inc.
    		  -2,472,237.5 -3,945,363   -923,944.5 1,879,796 -4,470,474    588,343                                            
      net income attributable to common stockholders
    		  -16,053,961.5 -19,445,607   -982,216.25 1,879,796 -4,625,804    588,343                                            
      weighted-average shares outstanding- basic and diluted
    		   572,018 1,773,086 31,518,861  4,014,261 871,319 13,673,433  12,908,520 12,908,520 12,908,520  8,982,520 7,486,120  7,486,120 7,235,031 38,113,391 33,399,597        26,351,483 25,427,407  24,075,225  18,938,283                      
      clinical laboratory service revenues
    		    220,552 326,326 325,480 324,730 331,020 336,700 522,298 2,174,697 3,941,102 4,514,295 2,942,561 3,893,810 3,200,122                                        
      cost of clinical laboratory service revenues
    		    245,223 248,458 282,592 322,099 293,679 377,522 495,963 1,279,121 2,230,616 2,519,691 2,237,800 2,950,064 2,621,639                                        
      total cost of revenues
    		    612,527 512,510 568,208 552,287 633,980 660,067 700,740 1,648,023 2,600,179 2,885,069                                           
      net loss attributable to applied dna sciences, inc.
    		    -3,304,175 -2,639,412    -1,105,100 -3,592,264 -3,099,766  -3,843,372 -663,219 -1,124,221  -4,511,093 -3,448,993 -1,516,800                                     
      unrealized (loss) on change in fair value of warrants classified as a liability - warrant modification
    		        -394,000                                                
      deemed dividend related to warrant modification
    		                                                        
      transaction cost allocated to warrant liabilities
    		                                                        
      unrealized loss on change in fair value of warrants classified as a liability
    		             -2,637,800                                           
      total cost of product and clinical laboratory service revenues
    		              2,493,119.75 3,257,113 3,056,568                                        
      loss on extinguishment of debt
    		                                                        
      gain on extinguishment of notes payable
    		                   839,945                                     
      unrealized gain on change in fair value of the common warrants
    		              635,175 1,758,200                                         
      transaction costs related to warrant liabilities
    		              -1,276,777                                          
      less: net income attributable to noncontrolling interest
    		                -855                                        
      cost of revenues
    		                 287,407.25 550,457 356,610 270,883 133,141 153,485 250,659 252,562 372,153 331,440 272,680 232,348 297,372 274,832 441,971 121,260                        
      depreciation and amortization
    		                 299,874 247,771 199,381 87,315 97,673 135,052 121,869 122,999 145,280 157,648 400,519 161,441 163,368 161,977 148,528 168,641 218,346 136,497 121,339 123,079 109,726 116,814 113,424 106,810 105,215 215,969 62,280 21,830 20,995 13,521 103,338 98,708 98,373 90,948 91,892 93,295 92,823 92,350 93,446 
      loss on extinguishment of convertible notes payable
    		                                                        
      net loss applicable to common stockholders
    		                   -1,516,800                                     
      revenues:
    		                                                        
      other income:
    		                                                        
      weighted-average shares outstanding - basic and diluted
    		                      30,470,753                                  
      weighted-average shares outstanding-
    		                                                        
      basic and diluted
    		                        30,112,057 30,112,057        22,542,176  21,444,335 17,362,573 15,456,566 13,515,518 814,155,727 808,248,340 789,894,847 703,852,716 721,142,161 680,399,988 649,922,615 576,091,498 594,931,878         
      other income
    		                           -6,639 -8,758                            
      net loss before provision for income taxes
    		                           -2,500,272.25 -2,610,849 -3,428,856  -2,440,225.75 -3,367,011 -2,926,270 -2,846,275.5 -1,670,882 -1,885,582 -7,828,644 -2,740,285.75 -1,919,057 -2,750,436  -3,492,000.25 -2,135,612 -3,127,631 -8,704,757 -1,345,858 -1,429,645 -1,543,882  -4,417,364 -2,154,995    -1,807,708 
      loss on conversion of promissory notes
    		                                     -980,842                   
      loss on change in fair value of warrant liability
    		                                     -2,994,540                   
      gain on change in fair value of warrant liability
    		                                  -748,635    -415,829 515,543 455,899  -1,536,307.25 707,289             
      income taxes
    		                                                       300 
      see the accompanying notes to the unaudited condensed consolidated financial statements
    		                                                        
      interest
    		                                          184.5 333 405            
      change in fair value of warrant liability
    		                                            -519,919            
      interest expense
    		                                              -273 -2,422 -42,833 -597,535 -640,542 -664,037 -255,297 -126,388 -186,604 -224,260 
      loss from change in fair value of warrant liability
    		                                             -6,332,599           
      revenue
    		                                              390,970 528,574 518,402 516,904 280,878 229,710     
      net loss from operations
    		                                              -1,185,160.5 -1,427,223 -1,501,049  -3,776,822 -1,490,958   -1,202,598 -1,583,448 
      net
    		                                              -1,345,858 -1,429,645  -2,409,905       
      net (loss) per share-basic and diluted
    		                                              -0.003          
      weighted-average shares outstanding-
    		                                                        
      basic and fully diluted
    		                                                583,619,169 490,282,252 26,004,836 351,962,281    275,204,070 
      net (loss) before provision for income taxes
    		                                                 -2,409,905       
      net (loss) per share-basic and fully diluted
    		                                                        
      sales
    		                                                    89,659 170,195 187,275 72,715 
      cost of sales
    		                                                    -14,801 -19,658 -14,036 -14,434 
      net income before provision for income taxes
    		                                                    -2,115,755 -2,596,935 -1,389,202  
      weighted-average shares outstanding-
    		                                                        
      basic
    		                                                    300,352,913 301,362,329 285,659,856  
      fully diluted
    		                                                    12,904,121 301,362,329 285,659,856  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2015-03-31 2014-12-31 2014-06-30 2013-12-31 2013-09-30 2013-06-30 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-06-30 2008-12-31 2008-09-30 2007-12-31 
                                              
        assets
      		                                        
        current assets:
      		                                        
        cash and cash equivalents
      		949,091 2,450,536 1,667,800 4,727,677 6,823,260 9,294,365 6,431,095 10,442,131 3,359,045 7,151,800 10,756,235 12,287,228 12,877,179 15,215,285 4,681,878 2,748,368 6,554,948 12,173,443 13,925,997 984,050 2,871,570 2,025,716 4,199,343 6,360,301 1,831,791 984,410 724,782 1,256,094  1,935,779 2,747,294 12,464  21,566 98,929      
        accounts receivable
      		303,265 546,739 237,400 199,047 689,887 911,502 362,013 513,871 450,757 255,502 682,701 1,967,710 4,053,477 3,067,544 2,858,966 3,857,275 2,804,039 737,347 2,186,442 1,160,304 1,114,541 518,274 749,354 672,638 587,655 361,782 296,994 442,767 323,643 232,611 208,587 177,833 63,029 57,068 35,626 16,006 16,425 70,999 75,150 14,007 
        inventories
      		115,395 89,954 84,102 338,723 348,866 468,580 438,592 469,871 377,291 330,027 276,422 366,085 477,014 602,244 1,172,320 1,300,629 1,369,933 429,116 720,538                      
        prepaid expenses and other current assets
      		1,310,814 1,273,286 242,153 338,447 568,398 601,508 815,970 416,427 402,953 389,241 524,904 758,530 924,682 1,058,056 554,639 593,149 568,881 356,414 586,207 155,593                     
        current assets of discontinued operations
      		 971 6,971 25,008                                     
        total current assets
      		2,678,565 5,111,486 2,238,426 5,628,902 8,430,411 11,275,955 8,047,670 11,842,300 4,590,046 8,126,570 12,240,262 15,379,553 18,332,352 19,943,129 9,267,803 8,499,421 11,297,801 13,696,320 17,419,184 2,299,947 4,135,228 2,714,782 5,075,107 7,207,035 2,561,009 1,398,547 1,101,813 1,806,580 1,203,735 2,218,294 3,032,171 292,972 242,103 181,291 159,640 73,990 356,597 174,228 294,888 1,222,704 
        property and equipment
      		173,729 193,922 242,720 511,203 683,887 638,483 553,233 530,735 539,319 838,270 1,168,038 1,575,309 1,865,772 2,222,988 2,557,475 2,807,852 3,023,915 2,576,616 2,422,628                      
        other assets:
      		                                        
        restricted cash
      		  750,000 750,000 750,000 750,000 750,000 750,000 750,000 750,000 750,000 750,000                            299,920 
        security deposit
      		 2,977 2,977                                      
        digital assets
      		1,335,076 7,130,817                                       
        digital asset receivable -from custodian
      		3,712,404                                        
        investment in digital asset trust
      		5,401,912 7,950,711                                       
        operating right of use asset
      		 48,861 193,249 334,402 472,390 607,288 739,162 868,081 1,117,317 1,237,762 1,355,508                              
        deferred offering costs
      		333,178 258,268 1,010,069                 287,831                     
        total assets
      		13,634,864 20,697,042 4,437,441 9,934,746 13,035,663 15,970,701 12,789,040 16,690,091 9,913,210 13,651,577 15,789,534 19,175,477 20,297,111 22,265,114 11,920,260 11,402,313 14,416,756 17,189,729 20,781,584 3,626,836 5,022,314 3,771,015 6,240,605 8,374,966 3,840,985 1,624,673 1,348,934 1,970,181 1,452,015 2,521,739 3,503,556 893,586 1,413,314 1,019,530 1,070,339 1,133,289 1,549,976 1,533,450 1,846,877 3,337,483 
        liabilities and equity
      		                                        
        current liabilities:
      		                                        
        accounts payable and accrued liabilities
      		1,469,692 2,140,519 2,258,376 1,564,707 1,409,628 1,610,972 1,793,427 2,440,688 2,023,876 2,270,388 2,127,908 2,895,578 3,056,123 3,621,751 3,527,131 2,521,353 2,991,343 1,321,753 1,780,072   1,259,439 1,209,974 966,977 1,533,478 808,803 592,009 378,910 388,232 787,178 768,061 1,316,371 967,550  1,149,808 1,058,318 940,692 12,795,577 12,821,171 12,360,093 
        operating lease liability, current
      		 48,861 193,250 334,403 472,390 558,426 545,912 533,679 510,028 498,598 487,425                              
        deferred revenue
      		3,772 16,047 12,285 12,285 12,285 217,215 58,785 51,285 54,035 76,435 275,885 283,298 273,880 563,557 757,264 457,538 281,000 252,807 350,057 227,810 524,361 348,624 324,988 148,503    25,000             
        total current liabilities
      		1,473,464 2,205,427 2,463,911 2,035,960 1,894,303 2,386,613 2,398,124 3,025,652 2,587,939 2,845,421 2,891,218 3,655,378 3,330,003 4,185,308 4,284,395 2,978,891 3,272,343 1,574,560 2,130,129 1,671,475 1,721,373 1,608,063 1,534,962 1,115,480  808,803 592,009 653,910 638,232 3,875,536 4,498,941 4,868,054 2,791,630  4,197,275 4,017,065 2,469,972 13,863,492 15,884,445 14,897,055 
        long term accrued liabilities
      		31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467 31,467                      
        warrants classified as a liability
      		  370 1,160 7,570 76,000 320,000 186,000 1,646,000 4,285,000 4,804,700 4,526,300 7,777,200                            
        total liabilities
      		1,504,931 2,236,894 2,495,748 2,946,702 2,811,455 3,421,056 3,820,955 4,455,636 5,784,808 8,779,165 8,595,466 9,207,256 11,138,670 9,356,175 5,125,562 3,010,358 3,303,810 1,606,027 2,161,596 1,671,475 1,721,373 3,459,786 4,358,127 3,758,929 1,533,478                
        bnb plus corps. stockholders’ equity:
      		                                        
        preferred stock, par value 0.001 per share...
      		                                        
        series a preferred stock, par value 0.001 per share...
      		                                        
        series b preferred stock, par value 0.001 per share...
      		                                        
        common stock, par value 0.001 per share...
      		5,669 4,774 1,663 902 6,331 54,114 10,314 10,301 13,722 13,659 12,909 12,909 12,909 12,909 8,984 7,488 7,488 7,488 7,488 17,370 17,362 827,332 807,850 786,527 733,524 656,935 646,183 626,990 591,413 513,233 473,326 352,523 346,366  296,591 275,204 261,889 238,491 205,359 190,761 
        additional paid in capital
      		416,951,861 416,617,812 381,463,459 381,150,267 364,896,649 339,918,754 318,805,058 318,757,698 307,848,612 307,384,647 306,091,402 305,751,360 305,492,756 305,399,008 298,624,138 297,228,192 295,228,272 295,191,444 294,781,015 211,412,483 210,872,495 197,138,651 194,059,887 190,523,121 184,549,123 170,356,909 169,117,881 167,929,140 166,032,584 162,399,302 160,387,716 153,112,072 149,396,907  143,205,386 142,080,731 140,803,386 138,123,762 133,133,354 130,955,788 
        accumulated deficit
      		-404,451,992 -397,786,765 -379,160,375 -373,888,601 -354,442,994 -327,219,390 -309,672,755 -306,376,012 -303,630,004 -302,447,147 -298,854,883 -295,755,117 -296,343,460 -292,500,088 -291,836,869 -288,843,858 -284,122,092 -279,610,999 -276,162,006 -209,474,492 -207,588,916 -197,654,754 -192,985,259 -186,693,611 -182,975,140 -177,711,896 -169,007,139 -167,239,859 -165,810,214 -164,266,332 -161,856,427 -157,439,063 -151,341,303  -146,628,913 -145,239,711 -141,985,271 -150,692,295 -147,376,281 -142,706,127 
        bnb plus corp. stockholders’ equity
      		12,505,538 18,835,821                                       
        noncontrolling interest
      		-375,605 -375,673 -363,054 -274,524 -235,778 -203,833 -174,532 -157,532 -103,928 -78,747 -55,360 -40,931 -3,764 -2,890 -1,555 133 -722 -4,231 -6,509                      
        total equity
      		12,129,933 18,460,148 1,941,693 6,988,044 10,224,208 12,549,645 8,968,085 12,234,455 4,128,402 4,872,412 7,194,068 9,968,221 9,158,441 12,908,939 6,794,698 8,391,955 11,112,946 15,583,702 18,619,988                      
        total liabilities and equity
      		13,634,864 20,697,042 4,437,441 9,934,746 13,035,663 15,970,701 12,789,040 16,690,091 9,913,210 13,651,577 15,789,534 19,175,477 20,297,111 22,265,114 11,920,260 11,402,313 14,416,756 17,189,729 20,781,584                      
        restricted cash, current
      		 750,000                                       
        noncurrent assets of discontinued operations
      		   11,264                                     
        intangible assets
      		   2,698,975 2,698,975 2,698,975 2,698,975 2,698,975 2,698,975 2,698,975        536,354 559,346                      
        current liabilities of discontinued operations
      		   124,565                                     
        deferred revenue, long term
      		   194,000 194,000 194,000 194,000 194,000 227,999 194,000                               
        operating lease liability, long term
      		     48,861 193,249 334,402 607,288 739,162 868,081                              
        deferred tax liability
      		   684,115 684,115 684,115 684,115 684,115 684,115 684,115                               
        commitments and contingencies
      		                                        
        bnb plus corp. stockholders’ equity:
      		                                        
        bnb plus corp., inc. stockholders’ equity
      		  2,304,747                                      
        applied dna sciences, inc. stockholders’ equity:
      		            9,162,205 12,911,829 6,796,253 8,391,822 11,113,668 15,587,933 18,626,497                      
        applied dna sciences, inc. stockholders’ equity
      		   7,262,568 10,459,986 12,753,478 9,142,617 12,391,987 4,232,330 4,951,159 7,249,428 10,009,152                             
        capitalized transaction costs
      		        217,553  275,726                              
        deposits
      		            98,987 98,997 94,982 95,040 95,040 95,053 95,040 61,988 61,988 55,488 51,260 51,260 51,260 36,276 36,276 36,276 36,276 35,976 23,458 23,458 8,322 8,322 8,322 8,322 8,322 8,322 8,322 8,322 
        right of use asset
      		           1,470,615                             
        lease liability, current
      		           476,502                             
        lease liability, long term
      		           994,111                             
        common warrant liability
      		             5,139,400 809,700                          
        goodwill
      		                 285,386 285,386                      
        promissory notes payable-current portion
      		                                        
        secured convertible notes payable , net of debt issuance costs
      		                                        
        promissory notes payable-long term portion
      		                                        
        secured convertible notes payable, net of debt issuance costs
      		                                        
        property, plant and equipment, net of accumulated depreciation
      		                   587,600 520,682                    
        intangible assets, net of accumulated amortization and impairment of 302,610 and 256,208 at march 31, 2015 and september 30, 2014, respectively
      		                   389,470                     
        liabilities and stockholders’ equity
      		                                        
        accounts payable and accrued liabilities, including related party accrued interest of 6,597 at september 30, 2014
      		                   1,443,665                     
        promissory notes payable, including 1,000,000 with a related party
      		                                        
        warrant liability
      		                     1,851,723 2,823,165 2,643,449  7,513,922               
        stockholders’ equity
      		                                        
        total stockholders’ equity
      		                   1,955,361 3,300,941 311,229 1,882,478 4,616,037 2,307,507 -6,698,052 756,925 1,316,271 813,783            
        total liabilities and stockholders’ equity
      		                   3,626,836 5,022,314 3,771,015 6,240,605 8,374,966 3,840,985 1,624,673 1,348,934 1,970,181 1,452,015            
        prepaid expenses
      		                    149,117 170,792 126,410 174,096 141,563 52,355 80,037 107,719 23,518 49,904 76,290 102,675 161,456 102,657 25,085 51,962 322,800 52,083 83,333 63,125 
        intangible assets:
      		                                        
        intellectual property, net of accumulated amortization and impairment of 279,664 and 256,208 at december 31, 2014 and september 30, 2014, respectively
      		                    304,416                    
        accounts payable and accrued liabilities, including related party accrued interest of -- and 6,597 at december 31, 2014 and september 30, 2014, respectively
      		                    1,197,012                    
        property, plant and equipment
      		                     649,417                   
        intellectual property, net of accumulated amortization and impairment of 232,751 and 163,403 at june 30, 2014 and september 30, 2013, respectively
      		                     351,328                   
        property, plant and equipment-net of accumulated depreciation of 491,643 and 409,629, respectively
      		                      716,763                  
        intellectual property, net of accumulated amortization and impairment of 186,604 and 163,403, respectively
      		                      397,475                  
        property, plant and equipment-net of accumulated depreciation of 409,629 and 251,958, respectively
      		                       695,995                 
        intellectual property, net of accumulated amortization and impairment of 163,403 and 0, respectively
      		                       420,676                 
        property, plant and equipment-net of accumulated depreciation of 337,593 and 251,958 respectively
      		                        664,106                
        intellectual property, net of accumulated amortization of 19,470 and 0, respectively
      		                        564,610                
        see the accompanying notes to the unaudited condensed consolidated financial statements
      		                                        
        property, plant and equipment-net of accumulated depreciation of 272,953 and 251,958 respectively
      		                         189,850               
        property, plant and equipment-net of accumulated depreciation of 251,958 and 210,862, respectively
      		                          210,845              
        capitalized finance costs-net of accumulated amortization of 1,892,236 and 1,806,261, respectively
      		                                        
        patents, net of accumulated amortization of 34,257
      		                                        
        intellectual property, net of accumulated amortization and write off of 9,430,900 and 9,158,056, respectively
      		                                        
        convertible notes payable, net of unamortized discount of 541,120
      		                                        
        see the accompanying notes to the consolidated financial statements
      		                                        
        property, plant and equipment-net of accumulated depreciation of 238,437 and 210,862, respectively
      		                           127,325             
        convertible notes payable, net of unamortized discount of -0- and 541,120,
      		                           250,000 250,000            
        cash
      		                            856,574    17,618   6,022 17,372 51,146 136,405 845,652 
        property, plant and equipment-net of accumulated depreciation of 226,047 and 210,862 respectively
      		                            121,056            
        intellectual property, net of accumulated amortization and write off of 9,339,952 and 9,158,056, respectively
      		                            90,948            
        property, plant and equipment-net of accumulated depreciation of 218,288 and 210,862, respectively
      		                             81,682           
        capitalized finance costs-net of accumulated amortization of 1,888,345 and 1,806,261, respectively
      		                             3,891           
        intellectual property, net of accumulated amortization and write off of 9,249,004 and 9,158,056, respectively
      		                             181,896           
        liabilities and deficiency in stockholders’ equity
      		                                        
        convertible notes payable, net of unamortized debt discount of 33,642 and 541,120, respectively
      		                             3,088,358           
        deficiency in stockholders’ equity
      		                                        
        total deficiency in stockholders’ equity
      		                             -1,353,797 -995,385 -3,974,468 -1,598,030  -3,126,936 -2,883,776 -919,996    
        total liabilities and deficiency in stockholders’ equity
      		                             2,521,739 3,503,556 893,586 1,413,314  1,070,339 1,133,289 1,549,976    
        property, plant and equipment-net of accumulated depreciation of 210,862 and 207,097 respectively
      		                              89,108          
        capitalized finance costs-net of accumulated amortization of 1,806,261 and 947,276, respectively
      		                              85,975          
        patients, net of accumulated amortization of 34,257
      		                                        
        intellectual property, net of accumulated amortization and write off of 9,158,056 and 8,794,265, respectively
      		                              272,844          
        advances from officers
      		                               600,000 50,000        
        convertible notes payable, net of unamortized discount of 541,120 and 545,920,
      		                              3,730,880          
        long term debt:
      		                                        
        convertible note payable-related party, net of unamortized discount of 5,286
      		                                219,714        
        deficiency in stockholders’ equity-
      		                                        
        capitalized finance costs-net of accumulated amortization of 1,678,872 and 947,276, respectively
      		                               213,365         
        intellectual property, net of accumulated amortization and write off of 9,067,109 and 8,794,265, respectively
      		                               363,791         
        convertible notes payable, net of unamortized discount of 1,088,317 and 545,920,
      		                               2,951,683         
        property, plant and equipment-net of accumulated depreciation of 207,097 and 199,119, respectively
      		                                3,765        
        capitalized finance costs-net of accumulated amortization of 947,276 and 615,611, respectively
      		                                522,489        
        patents, net of accumulated amortization of 34,257 and 34,112, respectively
      		                                        
        intellectual property, net of accumulated amortization and write off of 8,794,265 and 8,430,474, respectively
      		                                636,635        
        convertible notes payable, net of unamortized discount of 545,920 and 319,589, respectively
      		                                1,774,080        
        property, plant and equipment-net of accumulated depreciation of 204,750 and 199,119, respectively
      		                                 6,112       
        capitalized finance costs-net of accumulated amortization of 773,778 and 615,611, respectively
      		                                 96,222       
        intellectual property, net of accumulated amortization and write off of 8,703,317 and 8,430,474, respectively
      		                                 727,583       
        liabilities and deficiency in stockholders' equity
      		                                        
        property, plant and equipment-net of accumulated depreciation of 202,875 and 199,119, respectively
      		                                  7,987      
        capitalized finance costs-net of accumulated amortization of 726,641 and 615,611, respectively
      		                                  75,859      
        intellectual property, net of accumulated amortization and write off of 8,612,369 and 8,430,474, respectively
      		                                  818,531      
        advances, related party
      		                                  600,000      
        convertible notes payable, net of unamortized discount of 102,533 and 319,589,
      		                                  2,447,467      
        property, plant and equipment-net of accumulated depreciation of 201,472 and 199,119, respectively
      		                                   9,390     
        capitalized finance costs-net of accumulated amortization of 670,391 and 615,611, respectively
      		                                   132,109     
        intellectual property, net of accumulated amortization and write off of 8,521,422 and 8,430,474, respectively
      		                                   909,478     
        advances from related party
      		                                   150,000     
        convertible notes payable, net of unamortized discount of 191,253 and 319,589,
      		                                   2,808,747     
        property, plant and equipment-net of accumulated depreciation of 191,645 and 147,132, respectively
      		                                    19,217    
        capitalized finance costs-net of accumulated amortization of 585,940 and 464,274, respectively
      		                                    74,060    
        patents, net of accumulated amortization of 33,851 and 31,762, respectively
      		                                    406    
        intellectual property, net of accumulated amortization and write off of 8,339,526 and 8,066,682, respectively
      		                                    1,091,374    
        convertible notes payable, net of unamortized discount of 420,720 and 486,726, respectively
      		                                    1,529,280    
        property, plant and equipment-net of accumulated depreciation of 164,150 and 147,132, respectively
      		                                     46,712   
        capitalized finance costs-net of accumulated amortization of 548,058 and 464,274, respectively
      		                                     29,442   
        patents, net of accumulated amortization of 32,781 and 31,762, respectively
      		                                     1,476   
        intellectual property, net of accumulated amortization and write off of 8,157,631 and 8,066,682, respectively
      		                                     1,273,270   
        convertible notes payable, net of unamortized discount or 382,085 and 486,726, respectively
      		                                     1,067,915   
        deficiency in stockholders' equity-
      		                                        
        total deficiency in stockholders' equity
      		                                     -12,330,042 -14,037,568 -11,559,572 
        total liabilities and deficiency in stockholders' equity
      		                                     1,533,450 1,846,877 3,337,483 
        property, plant and equipment-net of accumulated depreciation of 147,132 and 82,825, respectively
      		                                      63,730  
        capitalized finance costs-net of accumulated amortization of 464,274 and 7,997, respectively
      		                                      113,226  
        patents, net of accumulated amortization of 31,762 and 25,445, respectively
      		                                      2,494  
        intellectual property, net of accumulated amortization and write off of 8,066,682 and 7,702,891, respectively
      		                                      1,364,217  
        convertible notes payable, net of unamortized discount of 486,726 and 359,595, respectively
      		                                      3,063,274  
        other current liabilities
      		                                       299,920 
        property, plant and equipment-net of accumulated depreciation of 97,967 and 82,825, respectively
      		                                       95,886 
        capitalized finance costs-net of accumulated amortization of 68,589
      		                                       366,411 
        patients, net of accumulated amortization of 27,158 and 25,445, respectively
      		                                       7,099 
        intellectual property, net of accumulated amortization and write off of 7,793,839 and 7,702,891, respectively
      		                                       1,637,061 
        convertible notes payable, net of unamortized discount
      		                                       2,237,042 
        preferred stock, par value 0.0001...
      		                                       6 
        see the accompanying notes to the condensed consolidated financial statements
      		                                        
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2021-09-30 2021-06-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2010-09-30 2010-06-30 2008-12-31 2007-12-31 
                                                          
          cash flows from operating activities:
        		                                                  
          net loss
        		-5,360,304 -3,984,109 -3,336,120 -2,668,713 -3,313,743 1,849,501 -4,493,783 -1,130,281 -3,615,651 -3,114,195 551,176 -3,844,246 -664,554 -4,720,911 -4,507,584 -3,446,715 -1,477,911 -2,686,757 -3,234,320 -3,475,283 -2,887,723 -2,146,210 -3,183,712 -2,854,678 -2,610,849 -3,428,856 -3,961,384 -2,415,076 -2,926,270 -496,035 -1,670,882 -1,885,576 -7,828,644 -2,105,518 -1,919,057 -2,750,436 -6,291,650 -3,718,471 -2,135,613 -3,127,631 -8,704,757 -1,767,280 -1,429,645 -1,543,882 -2,409,905 -4,417,364   -3,316,014 -2,132,744 
          net loss from discontinued operations
        		10,389                                                  
          net loss from continuing operations
        		-5,370,693                                                  
          adjustments to reconcile net loss from continuing operations to net cash from operating activities from continuing operations:
        		                                                  
          depreciation and amortization
        		128,564 78,346 118,675 58,580 76,985 134,163 186,326 298,951 329,681 349,146 344,504 338,918 327,680 320,751 299,874 247,771 87,315 97,672 135,052 121,869 122,999 145,280 157,648 146,542 161,441 163,368 161,977 148,528 218,346 136,497 121,339 123,079 109,726 116,814 113,423 106,810 105,215 101,239 62,280 21,830 20,995 13,521 103,338 98,707 98,374 90,948 93,295 92,823 108,984 107,804 
          deferred income tax benefit
        		                                                  
          impairment of intangible asset
        		                                                  
          loss on write-off of property and equipment
        		139,919 0 -77 5,289                                               
          unrealized gain on change in fair value of warrants classified as a liability
        		-790 -6,410 -68,430 -244,000 134,000 -5,160,000   -519,700 278,400                                         
          unrealized loss on change in fair value of warrants classified as a liability-warrant modification
        		    0 0                                             
          transaction costs allocated to warrant liabilities
        		    0 0                                             
          loss on issuance of warrants
        		    0 0                                             
          shares issued spindle earnout
        		                                                  
          stock-based compensation
        		21,648 24,889 26,511 28,973 30,248 30,336 171,004 340,705 341,495 340,042 258,604 93,748 272,916 1,699,920 36,828 410,429 154,304    238,738                              
          bad debt expense
        		                            10,000 13,246 18,971 0 2,779 2,877 734 1,144 15,000 7,415             
          change in operating assets and liabilities:
        		                                                  
          accounts receivable
        		-39,395 457,079 133,915 -557,212 151,857 -105,018 41,904 -195,254 410,389 1,250,839 2,085,767 -695,912 -468,029 -1,063,237 -2,089,077 1,462,488 72,647 298,560 879,807 -70,990 107,334 612,904 432,232 1,507,675 -74,874 823,434 828,076 -2,768,165 -4,480 -3,360,256 -946,924 -45,763 -282,502 -319,421 86,987 142,215 -91,716 -92,398             
          inventories
        		254,621 4,276 119,714 -29,988 31,279 -133,928 41,348 -47,264 -53,605 89,663 110,929 125,230 -47,605 69,304 -940,817 291,422 4,929 -89,386 -3,920 73,909 -1,440 20,250 12,380 50,052 -22,938 -29,758 -26,065 -160,976                       
          prepaid expenses, other current assets and deposits
        		93,317 170,166 33,110 214,462 -399,543 53,857 -67,331 -13,712                                           
          accounts payable and accrued liabilities
        		-344,059 222,064 -95,103 -299,618 15,227 -163,571 51,323 -383,423 280,602 -885,470 -160,259 -586,236 344,118 -169,991 1,620,066 -334,408 227,114 -41,220 198,713 142,374 221,605 102,682 -39,737 -191,815 -3,867 -290,769 -124,053 336,372 -320,825 1,316,567 223,062 -44,580 -253,997 235,321 -52,110 109,844 234,728 -98,867             
          deferred revenue
        		0 0 -114,930 158,430 7,500 0 -36,749 11,599 -5,450 -7,413 9,418 -289,677 -193,707 176,538 28,193 -97,250 -402,884 -170,027 18,583 -441,459 1,093,801 861,391 -8,775 -322,694 -298,089 -370,933 -477,881 1,888,805 -224,524 77,187 -22,947 -296,551 -59,001 234,738 -67,365 91,001 176,485              
          net cash from operating activities from continuing operations
        		-3,100,966                                                  
          cash flows from investing activities:
        		                                                  
          purchase of property and equipment
        		0 -10,923 -185,319 -116,879 -371,250 -21,826   87 -24,196   -242,661 -104,686 -906,418 -502,691 -4,500 -11,935 -52,051  -66,004 -155,167 -48,349             -15,071 -94,510 -423,054 -183,433   -97,041 -18,659        
          net cash from investing activities from continuing operations
        		0                                                  
          cash flows from financing activities:
        		                                                  
          net proceeds from exercise of warrants
        		292,305 723,056 984,172 508,600 0        3,700,000  0 0 269,434                                  
          capitalized offering costs
        		                                                  
          net proceeds from issuance of common stock and pre-funded warrants
        		0                                                  
          net cash from financing activities from continuing operations
        		125,964                                                  
          cash flows from discontinued operations
        		                                                  
          cash from operating activities
        		-90,362                                                  
          capital expenditures
        		0                                                  
          free cash flows
        		-90,362                                                  
          cash from investing activities
        		0                                                  
          net cash from discontinued operations
        		                                                  
          net decrease in cash, cash equivalents and restricted cash
        		      -209,405 -3,792,755  -1,530,993                                         
          cash, cash equivalents and restricted cash at beginning of period
        		0 0 0 7,181,095 0 0 0 7,901,800 0 0                                         
          cash, cash equivalents and restricted cash at end of period
        		-3,065,364 -2,083,125 -2,471,105 10,044,365 -4,011,036 7,292,491 -209,405 4,109,045 -3,604,435 -1,530,993                                         
          less: cash and cash equivablents of discontinued operations
        		                                                  
          cash, cash equivalents and restricted cash of continuing operations at end of period
        		-3,059,877                                                  
          supplemental disclosures of cash flow information:
        		                                                  
          cash paid during period for interest
        		                                                  
          cash paid during period for income taxes
        		                                                  
          non-cash investing and financing activities:
        		                                                  
          transaction costs included in accounts payable
        		   84,923                                               
          deemed dividend warrant modifications
        		0 15,500,244 23,919,429 14,907,223 0 0 155,330 77,757     0                                      
          warrants issued, cashlessly
        		704 -4,531 -15,780 20,921                                               
          property and equipment acquired and included in accounts payable
        		  -21,317 32,240 -271,767                                              
          change in provision for bad debts
        		 0 -2,300 7,723     16,810 34,169 0 -290,022                                       
          net cash used by discontinued operations
        		                                                  
          net increase in cash, cash equivalents and restricted cash
        		 -2,083,125 -2,471,105 2,863,270                                               
          less: cash and cash equivalents of discontinued operations
        		                                                  
          adjustments to reconcile net loss to net cash from operating activities:
        		                                                  
          net cash from operating activities
        		  -3,185,035 -3,326,074 -3,249,065 -3,494,660 -3,209,993 -3,757,679 -2,679,766 -1,369,193 214,388 -2,383,106 -3,258,620 -3,701,894 -4,712,077 -1,249,863 -1,283,105 -2,288,357 -1,513,668 -2,508,876 -1,128,582 -706,979 -2,572,772 -913,904 -1,866,265 -2,630,127 -2,068,888 -2,446,412 -2,720,746 -1,739,133 -1,255,006 -1,615,872 -2,355,835 -2,241,719 -2,008,483 -2,196,088 -2,066,448 -2,173,436 -1,807,806 -2,148,739 -1,740,372 -992,671 -1,124,421 -1,032,072 -811,515 -1,561,062 -926,448 -534,863 -585,259 -1,426,541 
          net cash from investing activities
        		  -185,319 -116,879 -371,250 -21,826   -924,669 -161,800 -54,339 45,000 -242,661 -104,686 -906,418 -502,691 -4,500 -11,935 -52,051 3,512 -66,004 -155,167 -48,349 -34,124 -17,618 -51,047 -42,647 -147,101 -66,096 -1,678,827 -226,866 -202,050 -30,825 -20,069 -99,941 -15,071 -94,510 -423,054 -767,513   -97,041 -18,659       94,508 
          net proceeds from issuance of common stock
        		  -84,923 5,797,623   2,934,774 45,566                                           
          net cash from financing activities
        		  899,249 6,306,223 -390,721 10,808,977 3,015,416 -35,076     14,034,688  0 0 253,610 703,589 3,043,999 1,650,112 0 -193,005 4,425,893 1,505,000 266,280 0 4,333,847 -13,986 7,857,565 0 11,227,966 -69,598 3,865,098 1,629,204    7,125,000 1,500 5,600,000 2,000,000 558,400    4,385,000 922,500 457,500 500,000 2,152,500 
          capitalized transaction costs
        		       -80,642                                           
          gain on sale of property and equipment
        		        0 0 0 -6,083                                       
          write-off of property and equipment
        		        0                                          
          cash paid for spindle asset purchase
        		                                                  
          proceeds from sale of property and equipment
        		        0 0 0 45,000                                       
          common stock issued for spindle asset purchase
        		                                                  
          deferred tax liability for spindle asset purchase
        		                                                  
          leased assets obtained in exchange for new operating lease liabilities
        		        0 0                                         
          capitalized transaction costs for assets purchase transaction
        		                                                  
          offering transaction costs included in accounts payable
        		     278,974                                             
          transaction costs for asset purchase included in accounts payable
        		                                                  
          unrealized loss on change in fair value of warrants classified as a liability
        		       -2,639,000    2,637,800                                       
          capitalized transaction costs included in accounts payable
        		       136,911                                           
          prepaid expenses and other current assets and deposits
        		        135,663 233,626 265,149 133,374 110,219 -24,268 -212,467 229,793 46,554 31,079 6,314  -27,331 -35,348 -173,921  69,614 -50,118 66,776  71,896  -34,737                    
          net proceeds from issuance of common stock and warrants
        		            10,334,688                                      
          fair value of warrants issued
        		            22,588,600                                      
          fair value of warrants exercised
        		                                                  
          deferred tax liability for spindle acquisition
        		                                                  
          issuance of stock options for payment of accrued bonus
        		            0 300,000                                     
          capitalized transaction costs for asset purchase transaction
        		                                                  
          property and equipment acquired, and included in accounts payable
        		          -298 20,619   49,537 -123,924     8,010 -15,247 30,247                            
          net decrease in cash and cash equivalents
        		           -2,338,106  -3,806,580      -855,252    556,972                        -77,363   
          cash and cash equivalents at beginning of period
        		           15,215,285 0 6,554,948 0 0 0 0 1,659,564  0 0 2,959,781  0 0 4,479,274  7,312,184  0 0 1,393,132  0 0 6,360,301  0 0 724,782  0 0 2,747,294   0 136,405 25,185 
          cash and cash equivalents at end of period
        		           12,877,179 10,533,407 2,748,368 -5,618,495 -1,752,554 -1,033,995 -1,596,703 3,137,844  -1,194,586 -1,055,151 4,764,553  -1,617,603 -2,681,174 6,701,586  12,382,907  9,746,094 -1,887,520 2,871,570  37,532 -2,211,159 4,199,343  -2,573,819 3,421,200 984,410  399,520 -1,079,205 1,935,779   -77,363 51,146 845,652 
          loss on disposal of property and equipment
        		                                                  
          impairment of goodwill and intangible assets
        		                                                  
          loss on extinguishment of convertible notes payable
        		              0 0                                   
          gain on extinguishment of notes payable
        		              0 0                                   
          public offering costs incurred
        		                                                  
          unrealized gain on change in fair value of the warrants classified as a liability
        		                                                  
          provision for bad debts
        		            259,451 10,000 22,384 -13,393 0 0 -8,633 0 3,435   55,752 346,921 15,601 5,646 10,578                       
          repayment of convertible notes
        		              0 0                                   
          net increase in cash and cash equivalents
        		            10,533,407  -5,618,495 -1,752,554  -1,596,703 1,478,280   -1,055,151 1,804,772   -2,681,174 2,222,312 -2,607,499 5,070,723 -3,417,960   1,478,438 -632,584 37,532 -2,211,159 -2,160,958 4,528,510 -2,573,819 3,421,200 259,628 -531,312 399,520 -1,079,205 -811,515 2,734,830   -85,259 820,467 
          interest paid in kind
        		              0 0 16,274                                  
          issuance of warrants in settlement of convertible notes payable
        		                                                  
          unrealized gain on change in fair value of the common warrants
        		                                                  
          fv of warrants issued
        		                                                  
          amortization of debt issuance costs
        		                4,827 4,628 4,492                                
          purchase of intangible asset
        		                                                  
          net proceeds from sale of common stock
        		              0                        0 0 2,000,000 558,400         
          net proceeds from sale of common stock and warrants
        		                -15,824 -14,475 2,493,999 112 0 -193,005 4,425,893 1,505,000 266,280 0 4,333,847 0 7,853,155 0 11,158,368 0 7,956,050                  
          proceeds from promissory notes
        		                0                                  
          deemed dividend-warrant repricing
        		                                                  
          deferred offering costs reclassified to additional paid in capital
        		                                                  
          intangible asset costs incurred, and included in accounts payable
        		                                                  
          change in operating assets and liabilities :
        		                                                  
          deferred offering costs reclassified to accounts payable
        		                                                  
          impact of adoption of new accounting pronouncements included in accumulated deficit
        		                0 0 493,223                                
          offering costs incurred, and included in accounts payable
        		                 -215,587 231,520    192,893                            
          stock-based compensation expense
        		                  490,244    231,113  566,376 537,904 1,458,020                        
          net proceeds from secured convertible promissory notes, related parties
        		                  550,000                                
          impairment expense
        		                                                  
          stock based compensation expense
        		                            396,991 491,078 1,015,362 517,319 1,998,524 289,617                 
          purchases of property and equipment
        		                                                  
          net proceeds from secured convertible promissory notes
        		                                                  
          cash and cash equivalents at beginning of year
        		                                                  
          cash and cash equivalents at end of year
        		                                                  
          cash paid during year for interest
        		                                                  
          cash paid during year for income taxes
        		                                                  
          non-cash investing and financing transactions:
        		                                                  
          debt issuance costs included in accounts payable and accrued liabilities
        		                                                  
          reclassification of deferred offering costs to additional paid in capital
        		                             0 0                    
          common stock issued in exchange for subscription receivable
        		                                                  
          reclassification of deferred offering costs to additional paid-in capital
        		                        0 0 13,986                        
          adjustments to reconcile net loss to net cash used in operating activities:
        		                                                  
          loss on sale of property and equipment
        		                                                  
          common stock issued for consulting services
        		                           -4 58,120 71,855 41,750   1 0 0 337,500              
          security deposit write-off
        		                                                  
          purchases of intangible assets
        		                                                  
          proceeds from exercise of warrants
        		                                      0            
          deferred offering costs
        		                                                  
          purchase and cancellation of previously issued warrants
        		                                     -10,000             
          common stock issued for cashless exercise of options
        		                                                  
          loss on sale of property, plant and equipment
        		                           0                       
          proceeds from sale of property, plant and equipment
        		                           0                       
          purchase of property, plant and equipment
        		                        -17,618 -51,047 -42,647 -78,051                       
          purchase of intangible assets
        		                           -69,050 -14,301 -48,871 -203,082                    
          proceeds from the exercise of warrants
        		                            4,410                      
          common stock issued in exchange for subscriptions receivable
        		                                                  
          intangible assets acquired, and included in accounts payable
        		                            17,841 -17,451 -43,704                    
          write-off of security deposit
        		                                                  
          common stock issued upon cashless exercise of options and warrants
        		                                                  
          property, plant and equipment acquired, and included in accounts payable
        		                            40,908 -12,325      -475 8,269              
          issuance of options to settle accrued liability
        		                            42,335                      
          change in fair value of warrant liability
        		                             0 0 0 2,994,540 -755,311 -515,543 -455,899 2,634,758 1,362,917 -707,289            
          loss on conversion of promissory notes
        		                             0 0 0 980,842                  
          purchase of assets under asset purchase agreement
        		                                                  
          common stock and warrants issued upon conversion of promissory notes payable and accrued interest
        		                                                  
          purchase and cancelation of previously issued warrants
        		                              0 0 -4,090,952                  
          common stock issued upon conversion of promissory notes payable
        		                              0                    
          offering costs incurred, and included in accounts payable and accrued liabilities
        		                              -149,744                    
          purchase of property plant and equipment
        		                            -51,795  -23,784 -167,050 -30,825                  
          cash paid during period for taxes
        		                                                  
          common stock issued for cashless exercise of options and warrants
        		                            49     -19,098 0 747 18,823              
          inventory
        		                                                  
          proceeds from promissory notes, including 1,000,000 from a related party
        		                                                  
          reclassification of warrants from liability to equity upon exercise of warrants
        		                                                  
          reclassification of warrants from liability to equity upon exercise
        		                                                  
          offering costs paid
        		                                                  
          prepaid expenses and deposits
        		                                -18,102 33,276 -60,058 11,448 47,686 -32,532             
          reclassification of deferred offering costs in connection with underwritten public offering
        		                                181,104                  
          impairment of intellectual property
        		                                                  
          amortization of capitalized financing costs
        		                                         0 0 3,891 82,084 127,390 173,498 47,137 83,784 60,592 
          amortization of debt discount attributable to convertible debentures
        		                                         0 0 33,642 507,478 547,197 177,188 61,840 417,934 324,047 
          fair value of vested warrants issued for service
        		                                     0             
          common stock issued in settlement of interest
        		                                         -405,095 0 393,528 114,411 2,037 93,000    
          fair value change from employee option modifications
        		                                                  
          purchase of assets under redweb asset purchase agreement
        		                                     0             
          net proceeds from sale of series a and series b preferred stock
        		                                                  
          proceeds from exercise of options and warrants
        		                                                  
          common stock issued upon conversion of series a and series b preferred stock
        		                                                  
          common stock issued in exchange for previously incurred debt and related accrued interest
        		                                                  
          fair value change from employee option modification
        		                                                  
          fair value of vested warrants issued for services
        		                                                  
          proceeds from sale of series a preferred stock
        		                                      0            
          proceeds from exercise of options
        		                                                  
          fair value of vested options issued to officers, directors and employees
        		                                   547,785 765,546 182,531 461,970 455,157 417,866 389,533 389,533 389,059 785,719 1,025,101 575,822 1,382,248 1,850,247  
          equity based compensation
        		                                       0 13,238   56,875 1,363 877,500     
          common stock issued in exchange for previously incurred debt
        		                                          0 2,872,000 1,150,000 20,037 1,231,849   50,275 
          see the accompanying notes to the unaudited condensed consolidated financial statements
        		                                                  
          fair value of warrants issued for financing costs
        		                                             0     
          property, plant and equipment acquired, included in accounts payable
        		                                                  
          increase in accounts receivable
        		                                       -46,015 -64,788 145,773 -119,124       -14,007 
          decrease in prepaid expenses and deposits
        		                                       27,080 27,682 27,682 -84,201 26,086 13,868 26,385 55,086 -77,572 31,250 37,875 
          increase in accounts payable and accrued liabilities
        		                                       921 216,793 628,195   19,117 -548,312  131,205  -855,607 
          loss from change in fair value of warrant liability
        		                                        6,332,599          
          net proceeds from (payments of) related party advances
        		                                                  
          net proceeds from issuance of convertible notes
        		                                             250,000 872,500 1,057,500 500,000  
          see the accompanying notes to the consolidated financial statements
        		                                                  
          changes in operating assets and liabilities:
        		                                                  
          increase in deferred revenue
        		                                                  
          non-cash transactions:
        		                                                  
          decrease in accounts payable and accrued liabilities
        		                                                  
          adjustments to reconcile net income to net cash from operating activities:
        		                                                  
          decrease in accounts receivable
        		                                            -24,024  -5,961 -21,442   
          cash flows from investing activities
        		                                                  
          change in assets and liabilities:
        		                                                  
          net proceeds from (repayments of) related party advances
        		                                                  
          cash paid during the year for interest
        		                                                  
          cash paid during the year for taxes
        		                                                  
          net proceeds from related party advances
        		                                                  
          cash paid during the period for interest
        		                                                  
          cash paid during the period for taxes
        		                                                  
          net income
        		                                              -2,115,755 -2,596,635   
          adjustments to reconcile net income to net used in operating activities:
        		                                                  
          reversal of accrued penalty charges
        		                                                  
          fair value of warrants issued in exchange for services rendered
        		                                                  
          stock based compensation
        		                                                  
          increase in restricted cash held in escrow
        		                                                  
          common stock issued in exchange for previously incurred debt and accrued interest
        		                                                2,860,000  
          adjustments to reconcile net loss to net used in operating activities:
        		                                                  
          common stock issued in exchange for services rendered
        		                                                 1,040,000 
          decrease (increase) in accounts receivable
        		                                                4,151  
          decrease (increase) in prepaid expenses and deposits
        		                                                  
          increase (decrease) in accounts payable and accrued liabilities
        		                                                234,405  
          increase in deferred expenses
        		                                                  
          decrease in restricted cash held in escrow
        		                                                 100,000 
          acquisition (disposal) of property and equipment
        		                                                  
          fair value of warrants issued for services
        		                                                  
          common stock issued for services
        		                                                 1,040,000 
          decrease in other assets
        		                                                 5,500 
          fair value of options and warrants issued in exchange for services rendered
        		                                                  
          income attributable to repricing of warrants and debt derivatives
        		                                                  
          decrease (increase) in restricted cash held in escrow
        		                                                  
          acquisition of property and equipment
        		                                                 -5,492 
          proceeds from convertible debentures held in escrow
        		                                                  
          common stock issued in exchange for repayment of debt and accrued interest
        		                                                  
          fair value of options and warrants issued to consultants for services
        		                                                  
          proceeds from issuance of convertible notes
        		                                                 2,152,500